newsfilter
← Latest News
GlobeNewswire·

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as of March 31, 2025,